Potential value of tripartite motif-containing 59 as a biomarker for predicting the prognosis of patients with lung cancer

A protocol for systematic review and meta-analysis

Jianfei Guo, MB\textsuperscript{a}, Ke Min, MM\textsuperscript{b}, Lichun Deng, MB\textsuperscript{c,*}

Abstract

Background: In recent years, related studies have revealed that tripartite motif-containing 59 (TRIM59) is related to the prognosis of lung cancer. However, these results have not been proved by any evidence. Therefore, this study evaluated the relationship between TRIM59 and the prognosis of lung cancer by carrying out meta-analysis. In addition, we explored the mechanism and related pathways of TRIM59 in lung cancer through bioinformatics analysis.

Methods: Comprehensive literature search was performed in China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Chinese Scientific and Journal Database, Wan Fang, Web of Science, PubMed, and EMBASE databases, and eligible studies were obtained based on the inclusion and exclusion criteria. The pooled hazard ratios and odds ratios were applied to assess the clinical value of TRIM59 expression for overall survival and clinicopathological features. Meanwhile, meta-analysis was conducted on the Stata 16.0. The mRNA expression level of TRIM59 in lung cancer was analyzed using Oncomine and Gene Expression Profiling Interactive Analysis (GEPIA) database. Gene Set Enrichment Analysis (GSEA) was used to predict the signaling pathways that TRIM59 might be involved in. The correlation between the expression level of TRIM59 in lung cancer and the abundance of immune cell invasion was analyzed by TIMER database. The survival analysis was verified by Kaplan–Meier Plotter database.

Results: The results of this meta-analysis would be submitted to peer-reviewed journals for publication.

Conclusion: In this study, the application of meta-analysis and bioinformatics analysis will provide evidence support for the study on the prognosis and mechanism of TRIM59 in lung cancer.

Abbreviations: CIs = confidence intervals, HRs = hazard ratios, TRIM59 = tripartite motif-containing 59.

Keywords: bioinformatics, lung cancer, meta-analysis, prognosis, protocol, tripartite motif-containing 59

1. Introduction

The incidence and mortality of lung cancer are the highest among malignant tumors, posing a great threat to human health, most of which are non-small cell lung cancer.\textsuperscript{[1–12]} At present, the main treatment methods for lung cancer patients\textsuperscript{[13,14]} include surgical resection, radiotherapy, chemotherapy, targeted therapy and immunotherapy. However, these treatments have their limitations and risk of cancer recurrence. How to scientifically and effectively treat lung cancer is still a great challenge facing the medical community. The occurrence and development of lung cancer is closely related to the abnormal gene expression and signaling pathway.\textsuperscript{[5]}

Tripartite motif-containing 59 (TRIM59) is a new member of the tripartite motif family, and it is associated with a variety of tumors.\textsuperscript{[6,7]} Studies have proved that TRIM59, as an oncogene, is up-regulated in lung cancer, stomach cancer, liver cancer, colorectal cancer and other tumors.\textsuperscript{[8–10] Moreover, TRIM59 can promote the proliferation and migration of tumor cells through a variety of pathways.\textsuperscript{[6,11–13]} TRIM59 is expected to be a new target for tumor diagnosis and treatment.

However, the expression of TRIM59 and its function in lung cancer are still poorly understood. Therefore, in this study, bioinformatics analysis and meta-analysis were used to explore the expression and potential function of TRIM59 in lung cancer,
so as to provide reference for relevant basic experiments and clinical translational studies.

2. Methods

2.1. Study registration

This meta-analysis protocol is based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P) statement guidelines. The PRISMA-P was registered on Open Science Framework, and the registration number is DOI 10.17605/OSF.IO/ZTGSE.

2.2. Data sources and retrieval strategy

A systematic literature search was conducted through July 2021 to identify relevant articles that are included in this meta-analysis and the search was carried out in the following databases: China National Knowledge Infrastructure, Chinese Biomedical Literature Database, Chinese Scientific and Journal Database, Wan Fang, Web of Science, PubMed, and EMBASE databases. The detailed search strategies are listed in Table 1.

2.3. Inclusion criteria for study selection

The inclusion criteria are as follows: All articles that describe the relationship between TRIM59 expression and survival outcome or clinicopathological parameters in patients with lung cancer; adequate data that are provided to calculate the odds ratio, hazard ratio (HR), and 95% confidence interval (CI); the expression of TRIM59 in lung cancer tissues that are determined by immunohistochemistry.

The exclusion criteria are as follows: the case report, review, letter, and conference abstract; articles describing overlapping studies; or studies with insufficient data.

2.4. Data collection and analysis

The literature screening process is displayed in Figure 1. The abstract and title were first read independently by 2 researchers. According to inclusion criteria and exclusion criteria, preliminary screening was conducted, and the included literatures were finally sorted out. The following data were obtained from each included study: the first author, publication year, country, ethnicity, sample size, detection method, clinicopathological parameters, the longest follow-up period, HR, and corresponding 95% CI. If the required data were not provided directly but as Kaplan–Meier curves, it is necessary to use Engauge Digitizer4.1 version to extract HR and its 95% CI from graphic survival curves.

2.5. Quality assessment

The Newcastle–Ottawa Scale (NOS) was used to perform the quality assessment of each included study. NOS score ≥6 indicates that the quality of the literature is high.

2.6. Measures of prognosis

Overall survival was taken as prognostic outcomes, and the results were expressed as HRs with 95% CIs.

2.7. Management of missing data

If there exists insufficient or missing data in the literature, we would only analyze the currently available data and discuss its potential value.

2.8. Statistical analysis

Meta-analysis was conducted on the Stata 16.0 (Stata Corporation, TX). HR and its 95% CIs were used to evaluate the relationship between TRIM59 expression and prognosis in patients with lung cancer. Pooled odds ratio and corresponding 95% CI were used to evaluate the association between TRIM59 expression and clinicopathological parameters in lung cancer patients. Cochran’s Q (chi-square) test and I2 statistics were applied to assess the heterogeneity among the studies. If P < .1 and I2 > 50% were considered as significant heterogeneity, the random-effects model was used or the fixed-effects model was used. P values in this study were 2-sided, and P < .05 indicated that there were statistical significances.

2.9. Additional analysis

2.9.1. Subgroup analysis. According to the detection methods, ethnicity, and the source of survival data, we conducted the subgroup.

| Table 1 |
| Search strategy in PubMed database. |

| Number | Search terms |
| --- | --- |
| #1 | Lung Neoplasms[MeSH] |
| #2 | Cancer of Lung[Title/Abstract] |
| #3 | Lung Cancer[Title/Abstract] |
| #4 | Pulmonary Cancer[Title/Abstract] |
| #5 | Pulmonary Neoplasms[Title/Abstract] |
| #6 | Cancer of the Lung[Title/Abstract] |
| #7 | Neoplasms, Lung[Title/Abstract] |
| #8 | Neoplasms, Pulmonary[Title/Abstract] |
| #9 | Cancer, Lung[Title/Abstract] |
| #10 | Cancer, Pulmonary[Title/Abstract] |
| #11 | Cancers, Lung[Title/Abstract] |
| #12 | Cancers, Pulmonary[Title/Abstract] |
| #13 | Lung Cancers[Title/Abstract] |
| #14 | Lung Neoplasm[Title/Abstract] |
| #15 | Neoplasm, Lung[Title/Abstract] |
| #16 | Neoplasm, Pulmonary[Title/Abstract] |
| #17 | Pulmonary Cancers[Title/Abstract] |
| #18 | Pulmonary Neoplasm[Title/Abstract] |
| #19 | Carcinoma, Non-Small-Cell Lung[MeSH] |
| #20 | Carcinoma, Non-Small Cell Lung[Title/Abstract] |
| #21 | Non-Small Cell Lung Cancer[Title/Abstract] |
| #22 | Non-Small-Cell Lung Carcinoma[Title/Abstract] |
| #23 | Non-Small-Cell Lung Cancer[Title/Abstract] |
| #24 | Carcinoma, Non-Small-Cell Lung[Title/Abstract] |
| #25 | Carcinomas, Non-Small-Cell Lung[Title/Abstract] |
| #26 | Lung Carcinoma, Non-Small-Cell[Title/Abstract] |
| #27 | Lung Carcinomas, Non-Small-Cell[Title/Abstract] |
| #28 | Non-Small-Cell Lung Carcinoma[Title/Abstract] |
| #29 | Non-Small-Cell Lung Carcinomas[Title/Abstract] |
| #30 | Small Cell Lung Carcinoma[MeSH] |
| #31 | Oat Cell Carcinoma of Lung[Title/Abstract] |
| #32 | Carcinoma, Small Cell Lung[Title/Abstract] |
| #33 | Oat Cell Lung Cancer[Title/Abstract] |
| #34 | Small Cell Cancer Of The Lung[Title/Abstract] |
| #35 | Small Cell Lung Cancer[Title/Abstract] |
| #36 | or1-35 |
| #37 | Tripartite motif-containing 59[Title/Abstract] |
| #38 | TRIM59[Title/Abstract] |
| #39 | or/37-38 |
| #40 | Prognosis[Title/Abstract] |
| #41 | Survival[Title/Abstract] |
| #42 | or/40-41 |
| #43 | #36 and #39 and #42 |
2.9.2. Sensitivity analysis. Sensitivity analysis was performed via sequential deletion of a single included study to test.

2.9.3. Reporting bias. Begg’s test and Egger’s test were carried out to evaluate the potential publication bias.\(^{19,20}\)

3. Bioinformatics analysis

The mRNA expression levels of TRIM59 in lung cancer and paracancerous tissues were analyzed using Oncomine database (https://www.oncomine.org/resource/main.html) and Gene Expression Profiling Interactive Analysis (GEPIA) database (http://gepia.cancer-pku.cn/). All lung cancer specimens with TRIM59 gene were selected from Kaplan–Meier plotter database for survival correlation analysis. RNASeq data of TRIM59 gene in lung cancer samples from The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga) were selected for Gene Set Enrichment Analysis (GSEA). The relationship between TRIM59 expression level and immune cell infiltration in lung cancer was analyzed by TIMER database.
4. Ethics

Our research data were derived from published literatures, because there were no patient recruitment and personal information collection. Therefore, ethical approval was not required.

5. Discussion

TRIM59 is located on human chromosome 3 and is a member of the C-XI subfamily. Apart from inheriting a highly conserved 3-segment domain, a TM domain is also involved in protein transmembrane localization at its C-terminal that is involved in the localization of TRIM59. TRIM59 protein is located in the endoplasmic omentum of cells and contains 403 amino acid residues. By mediating the interactions between proteins, the ubiquitination regulates the stability of the protein and promotes the disordered proliferation of tumor cells. TRIM59 plays a negative role in the regulation of immune signals through the activation of NF-kB and IRF3/IRF7 mediated signaling pathways. TRIM59 participates in SV40 Tag/p53/PRB and Ras/ERK/PJ3K/Akt oncogenic signaling pathways, regulates DNA synthesis in the S phase of the cell cycle, promotes cell division and proliferation, simultaneously upregulates the expression of cell cycle-related proteins, and ultimately induces tumor formation.

TRIM59 is not only involved in the molecular mechanism of lung cancer, but is also closely correlated to the clinicopathological characteristics and prognosis of lung cancer. The increased expression of TRIM59 indicates a poor clinical prognosis in patients with lung cancer, and may be used as a biomarker to evaluate the prognosis of patients suffering from lung cancer. In this study, the role of TRIM59 in the prognosis of lung cancer patients was analyzed through meta-analysis and bioinformatics.

Author contributions

Conceptualization: Lichun Deng, Jianfei Guo.
Data curation: Jianfei Guo.
Formal analysis: Jianfei Guo.
Funding acquisition: Lichun Deng.
Methodology: Ke Min.
Project administration: Lichun Deng.
Resources: Ke Min.
Supervision: Lichun Deng.
Validation: Ke Min.
Writing – original draft: Lichun Deng, Jianfei Guo, Ke Min.
Writing – review & editing: Lichun Deng, Jianfei Guo, Ke Min.

References

[1] Cai Z, Liu Q. Understanding the Global cancer statistics 2018: implications for cancer control. Sci China Life Sci 2021;64:1017–20.
[2] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
[3] Schneider BJ, Ismala N, Aerts J, et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol 2020;38:753–66.
[4] Sun A, Durocher-Allen LD, Ellis PM, et al. Guideline for the initial management of small cell lung cancer (limited and extensive stage) and the role of thoracic radiotherapy and first-line chemotherapy. Clin Oncol 2018;30:658–66.
[5] Han Q, Cheng P, Yang H, Liang H, Lin F. Altered expression of microRNA-365 is related to the occurrence and development of non-small-cell lung cancer by inhibiting TRIM25 expression. J Cell Physiol 2019;234:22321–30.
[6] Valiyeva F, Jiang F, Elmadawi A, et al. Characterization of the oncogenic activity of the novel TRIM59 gene in mouse cancer models. Mol Cancer Ther 2011;10:1229–40.
[7] Zhang P, Zhang H, Wang Y, Zhang Q, Qi Y. Tripartite motif-containing protein 59 (TRIM59) promotes epithelial ovarian cancer progression via the focal adhesion kinase (FAK)/AKT/matrix metalloproteinase (MMP) pathway. Med Sci Monit 2019;25:3366–73.
[8] Wang M, Chao C, Luo G, et al. Prognostic significance of TRIM59 for cancer patient survival: a systematic review and meta-analysis. Medicine 2019;98:e18024.
[9] Wang Y, Zhou Z, Wang X, et al. TRIM59 is a novel marker of poor prognosis and promotes malignant progression of ovarian cancer by inducing annexin A2 expression. Int J Biol Sci 2018;14:2073–82.
[10] Aierken G, Seyiti A, Alifu M, Kuerban G. Knockdown of tripartite-59 (TRIM59) inhibits cellular proliferation and migration in human cervical cancer cells. Oncol Res 2017;25:381–8.
[11] Zhou Z, Ji Z, Wang Y, et al. TRIM59 is up-regulated in gastric tumors, promoting ubiquitination and degradation of p53. Gastroenterology 2014;147:1043–54.
[12] Tan P, Ye Y, He L, et al. TRIM59 promotes breast cancer motility by suppressing p62-selective autophagic degradation of PDCD10. PLoS Biol 2018;16:e3000051.
[13] Shen H, Zhang J, Zhang Y, et al. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/FOXO signaling pathway. Pathophysiology 2019;26:50–60.
[14] Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ (Clin Res Ed) 2015;350:g7647.
[15] Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Stat Med 2002;21:3337–51.
[16] Tierney JF, Stewart LA, Gherzi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:1–16.
[17] Stang A. Critical evaluation of the Newcastle–Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25:603–5.
[18] Zhang Q, Jin Y, Li X, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism – a meta-analysis and systematic review. VASA Zeitschrift fur Gefasskrankheiten 2020;49:141–6.
[19] Lewis SJ, Zimmit S, Gunnell D, Smith GD. Bias in meta-analysis detected by a simple, graphical test. BMJ Clin Res 1997;315:629–34.
[20] Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–63.
[21] Li R, Weng L, Liu B, et al. TRIM59 predicts poor prognosis and promotes pancreatic cancer progression via the PI3K/AKT/mTOR-glycolysis signaling axis. J Cell Biochem 2020;121:1986–97.
[22] Geng B, Liang M, Qian L, et al. An TRIM59-CDK6 axis regulates growth and metastasis of lung cancer. J Cell Mol Med 2019;23:1458–69.
[23] Kondo T, Watanabe M, Hatakeyama S. TRIM59 interacts with ECSIT signaling pathway. Cancer Gene Ther 2019;26:1037–46.
[24] Tian H, Zhang D, Xu R, et al. Expression of TRIM59 in non-small cell lung cancer patients with thoracic radiation therapy. Cancer Gene Ther 2019;26:1037–46.
[25] Liang M, Chen X, Wang L, et al. Cancer-derived exosomal TRIM59 regulates macrophage NLRP3 inflammasome activation to promote lung cancer progression. J Exp Clin Cancer Res 2020;39:176.
[26] Lou M, Gao Z, Zhu T, et al. TRIM59 as a novel molecular biomarker to predict the prognosis of patients with NSCLC. Oncol Lett 2020;19:1400–8.
[27] Tian H, Zhang D, Xu R, et al. Expression of TRIM59 in non-small cell lung cancer and its correlation with prognosis. Zhongguo fei ai zai zhi 2020;23:21–8.
[28] Li C, Yang X, Qian H, et al. TRIM59’s expressions, clinical significance and correlation with c-myc, CDC25A in non-small cell lung cancer. Acta Univ Med Anhui 2020;2:287–91.
[29] Tang N, Bao Z, Liu N. Expression and clinical significance of IncRNA UFC1 and TRIM59 in non-small-cell lung cancer. Shandong Med J 2021;61:24–7.